Literature DB >> 19124065

Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems.

Jing Cui1, Bo Yu, Yu Zhao, Weiwei Zhu, Houli Li, Hongxiang Lou, Guangxi Zhai.   

Abstract

Curcumin is a poorly water-soluble drug and its oral bioavailability is very low. A new self-microemulsifying drug delivery system (SMEDDS) has been successfully developed to improve the solubility and oral absorption of curcumin. Suitable compositions of SMEDDS formulation were screened via solubility studies of curcumin and compatibility tests. The formulation of curcumin-loaded SMEDDS was optimized by a simplex lattice experiment design. The optimal formulation of SMEDDS was comprised of 57.5% surfactant (emulsifier OP:Cremorphor EL = 1:1), 30.0% co-surfactant (PEG 400) and 12.5% oil (ethyl oleate). The solubility of curcumin (21 mg/g) significantly increased in SMEDDS. The average particle size of SMEDDS-containing curcumin was about 21 nm when diluted in water. No significant variations in particle size and curcumin content in SMEDDS were observed over a period of 3 months at 4 degrees C. The spherical shape of microemulsion droplet was observed under TEM. The dissolution study in vitro showed that more than 95% of curcumin in SMEDDS could be dissolved in pH 1.2 or pH 6.8 buffer solutions in 20 min, however, less than 2% for crude curcumin in 60 min.The in situ absorption property of curcumin-loaded SMEDDS was evaluated in intestines of rats. The results showed the absorption of curcumin in SMEDDS was via passive transfer by diffusion across the lipid membranes. The results of oral absorption experiment in mice showed that SMEDDS could significantly increase the oral absorption of curcumin compared with its suspension. Our study illustrated that the developed SMEDDS formulation held great potential as a possible alternative to traditional oral formulations of curcumin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19124065     DOI: 10.1016/j.ijpharm.2008.12.009

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  48 in total

1.  Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice.

Authors:  Liu Zhongfa; Ming Chiu; Jiang Wang; Wei Chen; Winston Yen; Patty Fan-Havard; Lisa D Yee; Kenneth K Chan
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

2.  Preparation and bioavailability assessment of SMEDDS containing valsartan.

Authors:  Adhvait R Dixit; Sadhana J Rajput; Samir G Patel
Journal:  AAPS PharmSciTech       Date:  2010-02-25       Impact factor: 3.246

3.  Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations.

Authors:  Scheyla D V S Siqueira; Anette Müllertz; Kirsten Gräeser; Georgia Kasten; Huiling Mu; Thomas Rades
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

4.  Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil.

Authors:  Manish Kumar Jeengar; Shweta Shrivastava; Kala Nair; Sreenivasa Reddy Singareddy; Uday Kumar Putcha; M V N Kumar Talluri; V G M Naidu; Ramakrishna Sistla
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

5.  Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer.

Authors:  Abraham H Abouzeid; Niravkumar R Patel; Vladimir P Torchilin
Journal:  Int J Pharm       Date:  2014-01-17       Impact factor: 5.875

6.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes.

Authors:  Dongmei Sun; Xiaoying Zhuang; Xiaoyu Xiang; Yuelong Liu; Shuangyin Zhang; Cunren Liu; Stephen Barnes; William Grizzle; Donald Miller; Huang-Ge Zhang
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

7.  Pluronic micelles encapsulated curcumin manifests apoptotic cell death and inhibits pro-inflammatory cytokines in human breast adenocarcinoma cells.

Authors:  Foram U Vaidya; Rakesh Sharma; Sofiya Shaikh; Debes Ray; Vinod K Aswal; Chandramani Pathak
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-24

8.  Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.

Authors:  Robert E Carroll; Richard V Benya; Danielle Kim Turgeon; Shaiju Vareed; Malloree Neuman; Luz Rodriguez; Madhuri Kakarala; Philip M Carpenter; Christine McLaren; Frank L Meyskens; Dean E Brenner
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

9.  Development, characterization and permeability assessment based on caco-2 monolayers of self-microemulsifying floating tablets of tetrahydrocurcumin.

Authors:  Namfa Sermkaew; Kamonthip Wiwattanawongsa; Wichan Ketjinda; Ruedeekorn Wiwattanapatapee
Journal:  AAPS PharmSciTech       Date:  2013-01-15       Impact factor: 3.246

10.  Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice.

Authors:  Subhash Padhye; Sanjeev Banerjee; Deepak Chavan; Shubhangini Pandye; K Venkateswara Swamy; Shadan Ali; Jing Li; Q Ping Dou; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2009-08-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.